Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.
PMID: 11923351
2002
Journal of clinical microbiology
Abstract: Mutations conferring resistance to didanosine and lamivudine were detected in 2 (L74V and M184I; 14.2%) of 11 patients tested and in 4 (M184V; 57%) of 7 patients tested, respectively.
Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
Abstract: A single amino acid change from methionine 184 to valine in HIV-1 RT (RT(M184V)) has been observed clinically in response to abacavir treatment.
Abstract: In both DNA- and RNA-directed polymerization, a decrease in the efficiency of CBVTP utilization with respect to dGTP was found with RT(M184V), suggesting that this mutation confers resistance at the level of CBVMP incorporation.
Abstract: In contrast to CBVTP, D4GTP was found to be an excellent substrate for RT(WT) and no resistance was conferred by the M184V mutation, thus providing novel insight into structure-activity relationships for nucleoside-based inhibitors.
Abstract: The ability of the natural substrate, dGTP, or CBVTP to b
Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
PMID: 12003172
2002
Journal of biological regulators and homeostatic agents
Abstract: Among mutations associated with high-level resistance to RTI, T215Y was found in only 2 patients, M184V in 2 cases, T69D in another case, and K103N in only 1 patient, for a total of 6 patients (one carrying both T215Y and M184V) (1.7%).
Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
Abstract: During lamivudine monotherapy the M184V mutation was rapidly acquired and viral load rebounded.
Abstract: Resistance to lamivudine (mutation M184V) developed rapidly in all three arms.
Abstract: Zalcitabine monotherapy initially selected M184V mutants, but these were lost as therapy continued.
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Abstract: At week 16, the genotypes in isolates from the abacavir/lamivudine/zidovudine group were M184V alone (n = 3 cases), WT (n = 3) and M184V plus thymidine analogue mutations (TAMs) (n = 1).
Abstract: At week 48, the most common genotype was M184V alone in the abacavir/ lamivudine/zidovudine group (median vRNA 1-2 log,10 below baseline), and M184V with or without TAMs in patients originally assigned to lamivudine/zidovudine.
Abstract: CONCLUSIONS: Abacavir retained efficacy against isolates with the M184V genotype alone.
Abstract: Despite detectable M184V in 74% of patients on lamivudine/zidovudine, addition of abacavir with or without another antiretroviral therapy resulted in a reduction in vRNA, with 42 of 65 (65%) patients having week 48 vRNA < 400 copies/
The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.
Abstract: M184V is both common in the treated population and fitness-reducing.
Abstract: A number of studies, both of dual nucleoside therapy and HAART, have noted a residual treatment effect for 3TC despite the assumed or observed presence of M184V and high-level phenotypic resistance.
Abstract: The M184V mutation in the HIV-1 reverse transcriptase gene is primarily associated with rapid, high-level lamivudine (3TC) resistance.
Abstract: The full impact of M184V on therapeutic prospects will require further elucidation; ideally, the risk/benefit of preserving this substitution would be investigated in randomized trials.
Abstract: The speed and consistency with which this mutation is selected by 3TC under suboptimal viral suppression therefore makes M184V a
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
Abstract: Drug-resistant mutants with a methionine-to-valine substitution at position 184 of reverse transcriptase (M184V) emerged within 5 weeks of initiation of therapy in four newborn macaques infected with simian immunodeficiency virus (SIVmac251) and treated with lamivudine (3TC) or emtricitabine [(-)-FTC] (two animals per drug).
Abstract: These data demonstrate that the M184V mutation in SIV conferred a slightly reduced fitness but did not affect disease outcome.
Abstract: Thus, this animal model mimics the rapid emergence of M184V mutants of HIV-1 during 3TC therapy of human patients.
Abstract: To further evaluate the effect of the M184V mutation on viral fitness and virulence, groups of juvenile macaques were inoculated with the molecular clone SIVmac239 wit
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Abstract: Compared to placebo, significant reductions in HIV-1 RNA were observed for tenofovir DF-treated patients who had thymidine analog- (TAM), lamivudine- (M184V), NNRTI- or protease inhibitor-associated mutations.
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
PMID: 12069983
2002
Antimicrobial agents and chemotherapy
Abstract: We cultured lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) variants over an extended period of time in the presence of zidovudine and observed a premature reversion of the resistance-conferring M184V mutation.
Prevalence of genotypic resistance in untreated HIV patients in Spain.
PMID: 12072945
2002
European journal of clinical microbiology & infectious diseases
Abstract: Primary mutations in the reverse transcriptase gene were found in two (2.2%) samples: M41L, K70R and M184 V were found in one sample and K70R in another.
HIV mutation literature information.
PMID: 
2002
Journal of clinical microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT